Zobrazeno 1 - 10
of 16
pro vyhledávání: '"B A, Tjoa"'
We systematically map out the jamming transition of all 2D bidisperse mixtures of frictionless disks in the hard particle limit. The critical volume fraction, mean coordination number, number of rattlers, structural order parameters, and bulk modulus
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bcb2d2b4b8966b9e20941067cb9f7c1c
Publikováno v:
The Prostate. 43(1)
Infusion of dendritic cells (DCs) pulsed with PSMA peptides was considered possible in hormone-refractory metastatic prostate cancer patients both with or without prior treatment with a greater number of DCs and for lesser infusions than previously a
Autor:
B A, Tjoa, G P, Murphy
Publikováno v:
Seminars in surgical oncology. 18(1)
Treatments available for metastatic prostate cancer have failed to demonstrate significant curative potential. Current efforts are now directed towards developments of novel strategies for the treatment of metastatic prostate cancer. Cancer immunothe
Autor:
G P, Murphy, P, Snow, S J, Simmons, B A, Tjoa, M K, Rogers, J, Brandt, C G, Healy, W E, Bolton, D, Rodbold
Publikováno v:
The Prostate. 42(1)
Our purpose was to compare the importance of over 22 measurements used in evaluating the clinical responses of patients with metastatic or locally recurrent prostate cancer, treated by dendritic cell (DC) infusions with prostate-specific membrane ant
Autor:
B A, Tjoa, S J, Simmons, A, Elgamal, M, Rogers, H, Ragde, G M, Kenny, M J, Troychak, A L, Boynton, G P, Murphy
Publikováno v:
The Prostate. 40(2)
A phase II trial, involving infusions of autologous dendritic cells (DC) and two human histocompatibility antigen (HLA-A2)-specific prostate-specific membrane antigen (PSMA) peptides, was recently completed. Thirty percent of the participants, includ
Autor:
S J, Simmons, B A, Tjoa, M, Rogers, A, Elgamal, G M, Kenny, H, Ragde, M J, Troychak, A L, Boynton, G P, Murphy
Publikováno v:
The Prostate. 39(4)
Recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF; Leukine [sargramostim], Immunex Corp., Seattle, WA) was administered to a subgroup of 44 patients in a phase II clinical trial for prostate cancer using DC pulsed with HLA-A2
Autor:
G P, Murphy, B A, Tjoa, S J, Simmons, H, Ragde, M, Rogers, A, Elgamal, G M, Kenny, M J, Troychak, M L, Salgaller, A L, Boynton
Publikováno v:
The Prostate. 39(1)
A phase II trial was conducted to assess the efficacy of infusions of dendritic cells (DC) and two HLA-A2-specific prostate-specific membrane antigen (PSMA) peptides (PSM-P1 and -P2). This report describes the evaluation of 37 subjects admitted with
Autor:
G P, Murphy, B A, Tjoa, S J, Simmons, J, Jarisch, V A, Bowes, H, Ragde, M, Rogers, A, Elgamal, G M, Kenny, O E, Cobb, R C, Ireton, M J, Troychak, M L, Salgaller, A L, Boynton
Publikováno v:
The Prostate. 38(1)
A phase II trial was conducted to assess the efficacy of infusions of dendritic cells (DC) and two HLA-A2-specific PSMA peptides (PSM-P1 and -P2). This report describes thirty three subjects with hormone-refractory metastatic prostate cancer without
Autor:
B A, Tjoa, S J, Simmons, V A, Bowes, H, Ragde, M, Rogers, A, Elgamal, G M, Kenny, O E, Cobb, R C, Ireton, M J, Troychak, M L, Salgaller, A L, Boynton, G P, Murphy
Publikováno v:
The Prostate. 36(1)
A phase I trial involving patients with advanced prostate cancer was conducted to assess the safe administration of dendritic cells (DC) and HLA-A0201-specific prostate-specific membrane antigen (PSMA) peptides (PSM-P1 or -P2). Thirty-three of the ph
Autor:
M L, Salgaller, P A, Lodge, J G, McLean, B A, Tjoa, D J, Loftus, H, Ragde, G M, Kenny, M, Rogers, A L, Boynton, G P, Murphy
Publikováno v:
The Prostate. 35(2)
In this paper we describe our program for the immune monitoring of phase II participants given dendritic cell (DC)/prostate-specific membrane antigen (PSMA)-based immunotherapy, and we also present some initial findings.Phase II subjects received six